Cargando…

Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in Hypertriglyceridemia

Hypertriglyceridemia (HTG) is a prevalent medical condition in patients with cardiometabolic risk factors and is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), if left undiagnosed and undertreated. Current guidelines identify HTG as a risk-enhancing factor and,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mszar, Reed, Bart, Sarah, Sakers, Alexander, Soffer, Daniel, Karalis, Dean G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962307/ https://www.ncbi.nlm.nih.gov/pubmed/36835917 http://dx.doi.org/10.3390/jcm12041382

Ejemplares similares

Nonadherence to lipid‐lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease
por: Desai, Nihar R., et al.
Publicado: (2022)

Trends in PCSK9 Inhibitor Prescriptions before and after the Price Reduction in Patients with Atherosclerotic Cardiovascular Disease
por: Smith, Alex, et al.
Publicado: (2021)

Hypertriglyceridemia and Atherosclerotic Carotid Artery Stenosis
por: Miura, Yoichi, et al.
Publicado: (2022)

A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids
por: Karalis, Dean G.
Publicado: (2016)

Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis
por: Hernandez, Patricia, et al.
Publicado: (2021)

Association of cardiovascular risk profile with healthcare expenditure and resource utilization in chronic obstructive pulmonary disease, with and without atherosclerotic cardiovascular disease
por: Jafar, Zain, et al.
Publicado: (2020)

Heterogeneity in cardio-metabolic risk factors and atherosclerotic cardiovascular disease among Asian groups in the United States
por: Satish, Priyanka, et al.
Publicado: (2021)

Scope and Social Determinants of Food Insecurity Among Adults With Atherosclerotic Cardiovascular Disease in the United States
por: Mahajan, Shiwani, et al.
Publicado: (2021)

Hypertriglyceridemia and Cardiovascular Diseases: Revisited
por: Han, Seung Hwan, et al.
Publicado: (2016)

Top 10 dietary strategies for atherosclerotic cardiovascular risk reduction
por: Sikand, Geeta, et al.
Publicado: (2020)

Acute Pancreatitis Secondary to Severe Hypertriglyceridemia: Management of Severe Hypertriglyceridemia in Emergency Setting
por: Chaudhary, Ahmad, et al.
Publicado: (2017)

Hypertriglyceridemia in Antiretroviral Therapy
por: Imarhiagbe, Frank Aiwansoba, et al.
Publicado: (2005)

Association of Hypertriglyceridemia with All‐Cause Mortality and Atherosclerotic Cardiovascular Events in a Low‐Risk Italian Population: The TG‐REAL Retrospective Cohort Analysis
por: Arca, Marcello, et al.
Publicado: (2020)

Targeting hypertriglyceridemia to mitigate cardiovascular risk: A review
por: Toth, Peter P., et al.
Publicado: (2020)

Cumulative Burden of Financial Hardship From Medical Bills Across the Spectrum of Diabetes Mellitus and Atherosclerotic Cardiovascular Disease Among Non‐Elderly Adults in the United States
por: Mszar, Reed, et al.
Publicado: (2020)

Emerging Therapies for the Treatment of Atherosclerotic Cardiovascular Disease: From Bench to Bedside
por: Kumric, Marko, et al.
Publicado: (2023)

Impact of the COVID-19 pandemic on the management of risk factors in patients with stable atherosclerotic vascular disease
por: Karalis, Dean G., et al.
Publicado: (2023)

Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor
por: Tenenbaum, Alexander, et al.
Publicado: (2014)

Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very‐Low‐Density Lipoproteins
por: Lawler, Patrick R., et al.
Publicado: (2017)

Emerging Anti-Atherosclerotic Therapies
por: Gluba-Brzózka, Anna, et al.
Publicado: (2021)

The Novelty of Icosapent Ethyl in the Management of Hypertriglyceridemia and Alleviating Cardiovascular Risk
por: Khan, Muhammad Shoaib, et al.
Publicado: (2021)

Fellow's voice: Hypertriglyceridemia: Understanding the current guideline
por: Koneru, Sri Charitha
Publicado: (2022)

Androgen therapy and atherosclerotic cardiovascular disease
por: McGrath, K-CY, et al.
Publicado: (2008)

Digital Health in Focus of Predictive, Preventive and Personalised Medicine
por: Mszar, Reed
Publicado: (2021)

The End of Food Allergy: The First Program to Prevent and Reverse a 21(st) Century Epidemic
por: Mszar, Reed
Publicado: (2020)

Hypertriglyceridemia
por: Brahm, Amanda, et al.
Publicado: (2013)

Atherosclerotic Cardiovascular Risk in Japan
por: Nojiri, Shuko, et al.
Publicado: (2017)

A Cross-Sectional Study of the Current Management of Hypertriglyceridemia
por: Jar, Raghad A, et al.
Publicado: (2021)

Hypertriglyceridemia—Causes, Significance, and Approaches to Therapy
por: Santos-Baez, Leinys S., et al.
Publicado: (2020)

Nutritional Therapy for Asian Patients at Risk for Atherosclerotic Cardiovascular Disease
por: Lim, Hyunjung, et al.
Publicado: (2019)

Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease
por: Li, Sha, et al.
Publicado: (2022)

Hypertriglyceridemia and atherosclerosis
por: Peng, Jia, et al.
Publicado: (2017)

Genetics of Hypertriglyceridemia
por: Dron, Jacqueline S., et al.
Publicado: (2020)

Excess Risk for Atherosclerotic Cardiovascular Outcomes Among US Adults With HIV in the Current Era
por: Rosenson, Robert S., et al.
Publicado: (2019)

Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China
por: Bi, Lei, et al.
Publicado: (2022)

Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease
por: Gryka, Rebecca J., et al.
Publicado: (2017)

Familial hypertriglyceridemia: an entity with distinguishable features from other causes of hypertriglyceridemia
por: Cruz-Bautista, Ivette, et al.
Publicado: (2021)

FRI101 Marked Reduction In Severe Resistant Hypertriglyceridemia On PCSK9 Inhibitor
por: Kaul, Sabrina, et al.
Publicado: (2023)

Current Opinion on Endovascular Therapy for Emergent Large Vessel Occlusion Due to Underlying Intracranial Atherosclerotic Stenosis
por: Kang, Dong-Hun, et al.
Publicado: (2019)

Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations
por: Hetherington, Isabella, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rqncbg9o5lj150qtil9vfijtp4